Literature DB >> 20231629

Identification of unknown primary tumors in patients with neuroendocrine liver metastases.

Sam C Wang1, Justin R Parekh, Marlene B Zuraek, Alan P Venook, Emily K Bergsland, Robert S Warren, Eric K Nakakura.   

Abstract

BACKGROUND: For patients with neuroendocrine tumor (NET) liver metastases, resection of the primary tumor may prevent local complications (obstruction, ischemia, and bleeding) and improve survival. Despite preoperative evaluation, the primary tumor location may remain unknown.
DESIGN: Retrospective cohort analysis of pathology database from January 1, 1993, to August 15, 2008.
SETTING: Academic medical center. PATIENTS: One hundred twenty-three patients with NET liver metastases. MAIN OUTCOME MEASURES: Successful identification and resection of the primary tumor.
RESULTS: Fifteen patients underwent surgical exploration. The primary tumor was located in 13 patients (86.7%) in the small intestine and resected in 12 patients. Primary tumors in the small intestine found during surgical exploration were significantly smaller than those identified preoperatively (1.38 vs 1.91 cm, P = .03) and were often multifocal (54.2% [n = 15]). Computed tomography (34.6% [n = 78]) and somatostatin receptor scintigraphy (26.2% [n = 42]) were not sensitive in locating a primary NET in the gastrointestinal tract. Colonoscopy was sensitive in detecting colonic NETs (86.7% [n = 15]).
CONCLUSION: For patients with NET liver metastases and unknown primary tumor, surgical exploration effectively identifies and resects occult primary tumors that are often located in the small intestine. Primary tumors are usually small and multifocal, so careful palpation of the small intestine is essential. Before patients are considered for surgery, a multidisciplinary team assessment and evaluation consisting of computed tomography, somatostatin receptor scintigraphy, and upper and lower endoscopy should be done.

Entities:  

Mesh:

Year:  2010        PMID: 20231629     DOI: 10.1001/archsurg.2010.10

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  46 in total

1.  CUP Syndrome in Neuroendocrine Neoplasia: Analysis of Risk Factors and Impact of Surgical Intervention.

Authors:  Nehara Begum; Ulrich Wellner; Christoph Thorns; Georg Brabant; Martin Hoffmann; Conny Georg Bürk; Hendrik Lehnert; Tobias Keck
Journal:  World J Surg       Date:  2015-06       Impact factor: 3.352

2.  SATB2 in neuroendocrine neoplasms: strong expression is restricted to well-differentiated tumours of lower gastrointestinal tract origin and is most frequent in Merkel cell carcinoma among poorly differentiated carcinomas.

Authors:  Andrew M Bellizzi
Journal:  Histopathology       Date:  2019-11-15       Impact factor: 5.087

3.  Limitations of somatostatin scintigraphy in primary small bowel neuroendocrine tumors.

Authors:  Jessica E Maxwell; Scott K Sherman; Yusuf Menda; Donghong Wang; Thomas M O'Dorisio; James R Howe
Journal:  J Surg Res       Date:  2014-05-21       Impact factor: 2.192

4.  A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors.

Authors:  Jessica E Maxwell; Scott K Sherman; Kristen M Stashek; Thomas M O'Dorisio; Andrew M Bellizzi; James R Howe
Journal:  Surgery       Date:  2014-11-11       Impact factor: 3.982

Review 5.  Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

Authors:  Andrew M Bellizzi
Journal:  Hum Pathol       Date:  2019-12-17       Impact factor: 3.466

6.  Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.

Authors:  Jennifer C Carr; Scott K Sherman; Donghong Wang; Fadi S Dahdaleh; Andrew M Bellizzi; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe
Journal:  Ann Surg Oncol       Date:  2013-10-10       Impact factor: 5.344

7.  GIPR expression in gastric and duodenal neuroendocrine tumors.

Authors:  Scott K Sherman; Jessica E Maxwell; Jennifer C Carr; Donghong Wang; M Sue O'Dorisio; Thomas M O'Dorisio; James R Howe
Journal:  J Surg Res       Date:  2014-01-29       Impact factor: 2.192

8.  Alternative lengthening of telomeres predicts site of origin in neuroendocrine tumor liver metastases.

Authors:  Epameinondas Dogeas; Georgios Karagkounis; Christopher M Heaphy; Kenzo Hirose; Timothy M Pawlik; Christopher L Wolfgang; Alan Meeker; Ralph H Hruban; John L Cameron; Michael A Choti
Journal:  J Am Coll Surg       Date:  2014-01-10       Impact factor: 6.113

Review 9.  Biochemical Diagnosis and Preoperative Imaging of Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Jessica E Maxwell; Thomas M O'Dorisio; James R Howe
Journal:  Surg Oncol Clin N Am       Date:  2015-10-31       Impact factor: 3.495

10.  Differentiation of small bowel and pancreatic neuroendocrine tumors by gene-expression profiling.

Authors:  Jennifer C Carr; Erin A Boese; Philip M Spanheimer; Fadi S Dahdaleh; Molly Martin; Daniel Calva; Blanca Schafer; David M Thole; Terry Braun; Thomas M O'Dorisio; M Sue O'Dorisio; James R Howe
Journal:  Surgery       Date:  2012-12       Impact factor: 3.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.